Laparoscopic surgery for advanced ovarian cancer treatment
Official title: ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer: a Feasibility Prospective Study
Run by Azienda Ospedaliera di Padova · NCT05862740 · Data updated 2026-11-12
This study is testing if a less invasive type of surgery can safely and effectively remove advanced ovarian cancer in patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 62 (estimated) |
| Sponsor | Azienda Ospedaliera di Padova Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Padova, Padova, Veneto) |
| Status | Recruiting |
| Started | January 2, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | May 17, 2023 |
| Trial ID | NCT05862740 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are females aged 18 and above with advanced epithelial ovarian cancer (stage II-IV) who are eligible for primary or interval debulking surgery.
✕Probably not a fit
Patients with significant comorbidities or poor performance status that preclude radical surgery will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The ULTRA-LAP study investigates the safety, efficacy, and feasibility of laparoscopic debulking surgery (LDS) for patients with advanced ovarian cancer. It aims to determine the rate of complete resection of visible disease achieved through laparoscopy, as well as the rates of intra- and post-operative complications. Patients will undergo an exploratory laparoscopy to confirm eligibility, and if the surgical target cannot be met, they will receive neo-adjuvant chemotherapy before reconsideration for surgery. The study will enroll a minimum of 62 patients over approximately four years.
Why it matters
Potential benefit: If successful, this approach could lead to safer and more effective surgical options for patients with advanced ovarian cancer.
How similar studies have gone: While laparoscopic approaches have been explored in other studies, the specific application of LDS in advanced ovarian cancer is relatively novel and under investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with advanced epithelial ovarian cancer (II-IV Stage FIGO) candidates to PDS (primary debulking surgery) or IDS (interval debulking surgery: neoadjuvant chemotherapy followed by IDS). * Participant is willing and able to give informed consent for participation in the study. * Female aged 18 years or above. * Primary diagnosis of advanced epithelial ovarian cancer (tubal and peritoneal cancer included). Exclusion Criteria: * Comorbidities non-allowing for radical surgery * Poor Performance Status (Karnofsky Index \< 70) * Concomitant or past history of malignancy, regardless of treatment status * Recent or past story of pancreatitis or hepatitis * Recent or past story of pleural effusion or lung injuries or respiratory failure * Cardiac major pathologies
Where it's running
-
Azienda Ospedaliera Universitaria di Padova,
Padova, Padova, Veneto, Italy Recruiting
Study contacts
- Principal investigator: Roberto Tozzi, Professor — Azienda Ospedale Università di Padova
- Study coordinator: Matteo Marchetti, Doctor
- Email: matteomarchetti91@gmail.com
- Phone: 0039-049-8213445
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.